Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Browser does not support script.
Clinical Research in Southampton
Southampton Children's Hospital
A
A
A
Text only
| Accessibility | Privacy and cookies
"Helpful, informative, polite and friendly staff put my mind at ease"
Patient feedback
Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us
You are here:
Home
>
Search results
Search
Browse site A to Z
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Search results
Go To Advanced Search
Search
You could also try:
improbable (1)
,
doubtful (8)
,
not likely (447)
Pembrolizumab_200mg skin
Description
Regimen Chemotherapy Protocol SKIN CANCER Pembrolizumab (200mg) • Skin – Pembrolizumab (200mg) Indication • Pembrolizumab is recommended; -
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Pembrolizumab-200mg.pdf
Pembrolizumab Ver 1 skin
Description
Chemotherapy Protocol SKIN CANCER Pembrolizumab Pembrolizumab is currently available on a compassionate use basis only – not yet licensed in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinPembrolizumabVer1.pdf
Nivolumab Ver 1.1 skin
Description
Chemotherapy Protocol SKIN CANCER Nivolumab This regimen may require funding. Regimen Skin – Nivolumab Indication The treatment of advanced (unresectable or
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/NivolumabVer1.1.pdf
Nivolumab 480mg skin
Description
Chemotherapy Protocol SKIN CANCER Nivolumab (480mg-28 days) Regimen • Skin – Nivolumab (480mg-28 days) Indication • Nivolumab is recommended, within its mar
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-480mg.pdf
Nivolumab 240mg skin
Description
Chemotherapy Protocol SKIN CANCER Nivolumab (240mg-14 days) Regimen • Skin – Nivolumab (240mg-14 days) Indication • Nivolumab is recommended, within its mar
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-240mg.pdf
Ipilimumab-Nivolumab
Description
Chemotherapy Protocol SKIN CANCER IPILIMUMAB (3mg/kg)-NIVOLUMAB (1mg/kg) Regimen • Skin – Ipilimumab (3mg/kg)-Nivolumab (1mg/kg) Indication • Ipilimumab in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Ipilimumab-Nivolumab.pdf
Ipilimumab Ver 1
Description
Chemotherapy Protocol SKIN CANCER IPILIMUMAB Regimen Skin – Ipilimumab Indication Ipilimumab is recommended, within its marketing authorisation, as
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinIpilimumabVer1.pdf
Dabrafenib Trametinib Ver1
Description
Chemotherapy Protocol SKIN CANCER DABRAFENIB-TRAMETINIB Regimen Skin – Dabrafenib-Trametinib Indication The combination of dabrafenib and
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/SkinDabrafenibTrametinibVer1.pdf
Lenvatinib(60kg or greater)
Description
Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (60kg or greater) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib is in
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-60kg-or-greater-Ver1.pdf
Lenvatinib(59kg or less)
Description
Chemotherapy Protocol HEPATOCELLULAR CANCER LENVATINIB (59kg or less) Regimen • Hepatocellular – Lenvatinib Indication • Lenvatinib is indic
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Lenvatinib-59kg-or-less-.pdf
381
to
390
of
494
Previous
…
37
38
39
40
41
…
Next
Site policies
Report a problem with this page
Privacy and cookies
Site map
Translation
Last updated: 14 September 2019
Contact details
University Hospital Southampton NHS Foundation Trust
Tremona Road
Southampton
Hampshire
SO16 6YD
Telephone: 023 8077 7222
Useful links
Home
Getting here
What to do in an emergency
Research
Working here
Education
© 2014 University Hospital Southampton NHS Foundation Trust
Browser does not support script.
Browser does not support script.